CLAIMS

1. Use of Apoptosis Inhibitor of Macrophage (AIM), an AIM fragment having a biological activity of AIM, or a nucleic acid encoding the AIM or AIM fragment in the manufacture of a medicament for treating or preventing a neurodegenerative disease,
wherein the medicament is to be delivered into the brain,
wherein the biological activity of AIM comprises the activity of inducing phagocytosis of amyloid plaque in brain-derived microglia, and
wherein the neurodegenerative disease is a disease caused by amyloid plaque in the brain.

2. The use according to claim 1, wherein the nucleic acid encoding AIM or AIM fragment is incorporated in a viral vector.

3. The use according to claim 2, wherein the viral vector is a viral vector selected from the group consisting of adeno-associated virus, adenovirus, lentivirus, and Sendai virus.

4. The use according to claim 2, wherein the viral vector is an adeno-associated virus.

5. The use according to claim 4, wherein the adeno-associated virus is AAV serotype 5 (AAV5) or AAV serotype 9 (AAV9).

6. The use according to any one of claims 1 to 5, wherein the neurodegenerative disease is selected from the group consisting of Alzheimer’s disease, Parkinson’s disease, and Lewy body dementia.